AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (recAP) as a treatment for Acute Kidney Injury (AKI), Ulcerative Colitis (UC), and Hypophosphatasia (HPP)
AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (recAP) as a treatment for Acute Kidney Injury (AKI), Ulcerative Colitis (UC), and Hypophosphatasia (HPP).